Delay and inequalities in the treatment of idiopathic pulmonary fibrosis: the case of two Nordic countries
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Idiopathic pulmonary fibrosis (IPF) is characterized by progressive loss of lung function with high mortality within the first 5 years from diagnosis. In 2011–2014, two drugs, pirfenidone and nintedanib, have been approved worldwide for prevention of IPF progression. National IPF-registries have been established in both Finland and Sweden. Our study explored potential differences in the care of IPF in these two countries. Patients included consecutively in the Finnish and Swedish IPF-registries from January 1, 2014 through December 31, 2016 were included in the study. Data on demographics and lung function at the time of inclusion were collected. Access to antifibrotic drugs and data on disease outcomes, mortality and the proportion of patients who underwent lung transplantation, was collected during a 3-year follow up. One-hundred and fifty-two patients from the Finnish and 160 patients from the Swedish IPF-cohorts were included in the study. At inclusion, Finnish patients were significantly older than the Swedish patients (74.6 years vs 72.5 years, p = 0.017). The proportion of non-smokers was significantly higher in the Finnish cohort (41.7% vs 26.9%, p = 0.007). Forced vital capacity (FVC), % of predicted (78.2 vs 71.7 for Finnish and Swedish patients, respectively, p = 0.01) and diffusion capacity for carbon monoxide (DL CO ), % of predicted (53.3 vs 48.2 for Finnish and Swedish patients, respectively, p = 0.002) were significantly higher in the Finnish cohort compared to the Swedish cohort at the time of inclusion. During the 3-year follow up period, 45 (29.6%) Finnish and 111 (69.4%) Swedish patients, respectively, were initiated on treatment with an antifibrotic drug (pirfenidone or nintedanib) ( p < 0.001). When comparing possible determinants of treatment, patients with higher FVC % were less likely to start antifibrotic drugs (OR 0.96, 95%CI 0.93–1.00, p < 0.024). To be resident in Sweden was the main determinant for receiving antifibrotic drugs (OR 5.48, 95%CI 2.65–11.33, p < 0.0001). No significant difference in number of deaths and lung transplantation during the follow up period was found. This study highlights differences concerning how IPF patients are treated in Finland and Sweden. How these differences will influence the long-term outcome of these patients is unknown.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
Raghu, G., Rochwerg, B., Zhang, Y., Garcia, C. A. C., Azuma, A., Behr, J., Brozek, J. L., Collard, H. R., Cunningham, W., Homma, S., et al. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201506-1063st · Cited by 1,916
Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial
Vancheri, C., Kreuter, M., Richeldi, L., Ryerson, C. J., Valeyre, D., Grutters, J. C., Wiebe, S., Stansen, W., Quaresma, M., Stowasser, S., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201706-1301oc · Cited by 305 · cited 1×
“Two drugs (pirfenidone and nintedanib) have shown to slow down the decline of lung function in IPF patients, and combined treatments are currently under clinical investigation [2, 3].”
BackgroundReference Values for Lung Function Tests in Men: Regression Equations with Smoking Variables
Hedenström, H., Malmberg, P., & Fridriksson, H. V. (1986) · Upsala Journal of Medical Sciences · doi:10.3109/03009738609178670 · Cited by 288 · cited 1×
“Percent of predicted values for lung function were reported with the Finnish reference values from 1982 [14] in the Finnish registry and with the Swedish reference values in the Swedish registry [15, 16].”
ResultReference values for lung function tests in females. Regression equations with smoking variables.
Hedenström, H., Malmberg, P., & Agarwal, K. (1985) · PubMed · Cited by 243
Spirometric Studies in Non-Smoking, Healthy Adults
Viljanen, A. A., Halttunen, P. K., Kreus, K.-E., & Viljanen, B. C. (1982) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365518209168377 · Cited by 237
Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume
Kolb, M., Richeldi, L., Behr, J., Maher, T. M., Tang, W., Stowasser, S., Hallmann, C., & du Bois, R. M. (2017) · Thorax · doi:10.1136/thoraxjnl-2016-208710 · Cited by 235
Salmela, E., Lappalainen, T., Fransson, I., Andersen, P. M., Dahlman-Wright, K., Fiebig, A., Sistonen, P., Savontaus, M.-L., Schreiber, S., Kere, J., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003519 · Cited by 183 · cited 1×
“It is shown that there are significant genetic differences between these two populations but also within Finland between subpopulations in Eastern and Western Finland [19, 20].”
Background
Research works printed but not linked: 1
- Myllarniemi MKM, Kaunisto J, Kelloniemi K, Kankaanranta H, Hodgson U, et al (2014). The Majority Of IPF Patients Are Diagnosed At A Mild Or Moderate Disease Stage In Finland - Baseline Data From The FinnishIPF Study. American Thoracic Society Conference 2014, Am J Respir Crit Care Med 189(A6404). https://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2014.189.1_MeetingAbstracts.A6404 . · doi:10.1164/ajrccm-conference.2014.189.1_meetingabstracts.a6404
Cited by
Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat
Maher, T. M., & Strek, M. E. (2019) · Respiratory Research · doi:10.1186/s12931-019-1161-4 · Cited by 265
Behr, J., Prasse, A., Wirtz, H., Koschel, D., Pittrow, D., Held, M., Klotsche, J., Andreas, S., Claussen, M., Grohé, C., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.02279-2019 · Cited by 198
Demographics and survival of patients with idiopathic pulmonary fibrosis in the FinnishIPF registry
Kaunisto, J., Salomaa, E.-R. M., Hodgson, U., Kaarteenaho, R. L., Kankaanranta, H., Koli, K. M., Vahlberg, T. J., & Myllärniemi, M. (2019) · ERJ Open Research · doi:10.1183/23120541.00170-2018 · Cited by 121
Self-citationGao, J., Kalafatis, D., Carlson, L., Pesonen, I., Li, C., Wheelock, Å. M., Magnusson, J. M., & Sköld, C. M. (2021) · Respiratory Research · doi:10.1186/s12931-021-01634-x · Cited by 79
“In Sweden, anti-fibrotic drugs are completely reimbursed, which results in a large number of patients being on treatment [34].”
BackgroundSelf-citationSuzuki, Y., Aono, Y., Kono, M., Hasegawa, H., Yokomura, K., Naoi, H., Hozumi, H., Karayama, M., Furuhashi, K., Enomoto, N., et al. (2020) · Respirology · doi:10.1111/resp.13943 · Cited by 58
Metadata
- Authors
- Pesonen, I., Carlson, L., Murgia, N., Kaarteenaho, R., Sköld, C. M., Myllärniemi, M., & Ferrara, G.
- Affiliations
- Karolinska University Hospital (SE)
- University of Perugia (IT)
- Oulu University Hospital (FI)
- University of Helsinki (FI)
- Corresponding author
- Pesonen, Ida
- Venue
- Multidisciplinary Respiratory Medicine
- Publisher
- Mattioli1885
- Published
- 2018-05-14
- Volume
- 13
- Issue
- 1
- Pages
- 14-14
- ISSN
- 1828-695X (ISSN-L)
- 2049-6958
- PMC
- PMC5950183
- OpenAlex
- W2806388389
- Cited by
- 25
- References
- 23
- Citations by year
- 2026: 1 · 2024: 3 · 2023: 3 · 2022: 2 · 2021: 7 · 2020: 6 · 2019: 3
- FWCI
- 3.01
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (tdm)
- Locations
- Multidisciplinary Respiratory Medicine (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Työväentutkimus Vuosikirja (submittedVersion)
- Työväentutkimus Vuosikirja (submittedVersion, other-oa)
- Institutional Research Information System University of Ferrara (University of Ferrara) (submittedVersion, cc-by)
- Funders
- Sigrid Juséliuksen Säätiö
- Hengityssairauksien Tutkimussäätiö
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Keywords
- idiopathic pulmonary fibrosis, antifibrotic agents, pirfenidone, nintedanib, treatment delay, health care access, lung function, forced vital capacity, diffusion capacity, lung transplantation, mortality, Finland, Sweden, cross-national comparison, smoking status, age at diagnosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Delay and inequalities in the treatment of idiopathic pulmonary fibrosis: the case of two Nordic countries. https://app.cochat.ai/papers/10.1186/s40248-018-0126-7
- The paper
- Pesonen, I., Carlson, L., Murgia, N., Kaarteenaho, R., Sköld, C. M., Myllärniemi, M., & Ferrara, G. (2018). Delay and inequalities in the treatment of idiopathic pulmonary fibrosis: the case of two Nordic countries. Multidisciplinary Respiratory Medicine. https://doi.org/10.1186/s40248-018-0126-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.